Role of selective cholesterol absorption inhibition in the management of dyslipidemia

Current Atherosclerosis Reports

Volumn 6, Issue 1, 2004, Pages 52-59

  Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CIMETIDINE; DIGOXIN; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; SIMVASTATIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; WARFARIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; MYOPATHY; REVIEW; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3142547337     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-004-0116-4     Document Type: Review

References (48)

1. Sueta CA, Chowdhury M, Boccuzzi SJ, et al.: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999, 83:1303-1307.
2. Fonarow GC, French WJ, Parsons LS, et al.: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001, 103:38-44.
3. Pearson TA, Laurora I, Chu H, Kafonek S: The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459-467.
4. Leitersdorf E: Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management. Eur Heart J 2001, 3(suppl E):E17-E23.
5. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH: Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001, 111:185-191.
6. Simpson RJ Jr, Alexander CM, Weiss TW, et al.: Initiation of treatment with statins at doses below the recommended starting dose and subsequent titration rates in a large group of high-risk patients [abstract]. Circulation 2001, 104:11-829.
7. Knapp HH, Schrott H, Ma P, et al.: Efficacy and safety of combination sinivastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001, 110:352-360.
8. Rader DJ: Future outlook: changing perspectives on best practice. Am J Manag Care 2002, 8(suppl 2):S40-S44.
9. Gagne C, Bays HE, Weiss SR, et al.: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1084-1091.
10. Gagne C, Gaudet D, Bruckert E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475.
11. Davidson MH, McGarry T, Bettis R, et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 40:2125-2134.
12. Ballantyne CM, Houri J, Notarbartolo A, et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415.
13. Melani L, Mills R, Hassman D, et al.: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart 12003, 24:717-728.
14. Kerzner B, Corbelli J, Sharp S, et al.: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003, 91:418-424.
15. Brewer HB Jr: Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations. Am J Manag Care 2002, 8(2 suppl):S23-S28.
16. Van Heek M, France CF, Compton DS, et al.: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997, 283:157-163.
17. Van Heek M, Farley C, Compton DS, et al.: Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001, 134:409-417.
18. Davis HR, Compton DS, Hoos L, et al.: Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption [abstract]. Eur Heart J 2000, 21(suppl):636.
19. Van Heek M, Farley C, Compton DS, et al.: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000, 129:1748-1754.
20. Dietschy JM: Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr 1997, 65(suppl 5):1581S-1589S.
21. Shepherd J: The role of the exogenous pathway in hypercholesterolemia. Eur Heart J 2001, 3(suppl E):E2-E5.
22. Thompson GR, O'Neill F, Seed M: Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 2002, 23:200-206.
23. Sparrow CP, Patel S, Baffic J, et al.: A fluorescent cholesterol analog traces cholesterol absorption in hamsters and is esterified in vivo and in vitro. J Lipid Res 1999, 40:1747-1757.
24. Patrick JE, Kosoglou T, Stauber KL, et al.: Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002, 30:430-437.
25. Ezzet F, Wexler D, Statkevich P, et al.: The plasma concentration and LDL-C relationship in patients receiving ezotimibe. J Clin Pharmacol 2001, 41:943-949.
26. Sudhop T, Lutjohann D, Kodal A, et al.: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943-1948.
27. Reyderman L, Kosoglou T, Statkevich P, et al.: No pharmacokinetic drug interaction between ezetimibe and lovastatin [abstract]. Clin Pharm Ther 2001, 69:66.
28. Reyderman L, Statkevich P, Kosoglou T, et al.: No pharmacokinetic drug interaction between ezetimibe and either cerivastatin or fluvastatin [abstract]. AAPS Pharm Sci 2001, 3(suppl 3). http://www.aapspharmaceutica.com/search/abstract_view.asp?id=331.
29. Zhu Y, Statkevich P, Kosoglou T, et al.: Lack of a pharmacokinetic interaction between ezetimibe and atorvastatin [abstract]. Clin Pharmacol Ther 2001, 69:68.
30. Kosoglou T, Meyer I, Musiol B, et al.: Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin [abstract]. Atherosclerosis 2000, 151:135.
31. Kosoglou T, Seiberling M, Statkevich P, et al.: Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin [abstract]. J Am Coll Cardiol 2001, 37(suppl A):229A.
32. Kosoglou T, Statkevich P, Bauer KS, et al.: Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of digoxin [abstract]. AAPS Pharm Sci 2001, 3(suppl 3). http://www.aapspharmaceutica.com/search/abstract_view.asp?id=290.
33. Kosoglou T, Fruchart JC, Guillaume M, et al.: Coadministration of ezetimibe and fenofibrate leads to favorable effects on apo CIII and LDL subfractions [abstract]. Atheroscler Suppl 2001, 2(suppl):89.
34. Kosoglou T, Guillaume M, Sun S, et al.: Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe [abstract]. Atheroscler Suppl 2001, 2(suppl):38.
35. Krishna G, Kosoglou T, Ezzet F, et al.: Effect of cimetidine on the pharmacokinetics of ezetimibe [abstract]. AAPS Pharm Sci 2001, 3(suppl 3). http://www.aapspharmaceutica.com/search/abstract_view. asp?id =304.
36. Statkevich P, Zhu Y, Kosoglou T, et al.: Ezetimibe (SCH 58235) does not affect the pharmacokinetics of simvastatin [abstract]. Clin Pharmacol Ther 2000, 67:146.
37. Statkevich P, Reyderman L, Kosoglou T, et al.: Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide [abstract]. Clin Pharmacol Ther 2001, 69:P67.
38. Keung AC, Kosoglou T, Statkevich P, et al.: Ezetimibe does not affect the pharmacokinetics of oral contraceptives [abstract]. Clin Pharmacol Ther 2001, 69:P55.
39. Bauer KS, Kosoglou T, Statkevich P, et al.: Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin [abstract]. Clin Pharmacol Ther 2001, 69:P5.
40. Reyderman L, Kosoglou T, Maxwell SE, et al.: Lack of pharmacokinetic drug interaction between ezetimibe and fenofibrate [abstract]. AAPS Pharm Sci 2001, 3(suppl 3). http://www.aapspharmaceutica.com/search/abstract_view.asp?id=326.
41. Dujovne CA, Ettinger MP, McNeer JF, et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1092-1097.
42. Knopp RH, Gitter H, Truitt T, et, al.: Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003, 24:729-741.
43. Thompson GR: Familial hypercholesterolaemia. In Lipoproteins in Health and Disease. Edited by Betteridge DJ, Illingworth DR, Shepherd J. London: Arnold; 1999:675-692.
44. Stein E, Stender S, Mata P, et al.: Coadministration of ezetimibe plus atorvastatin [abstract]. Atheroscler Suppl 2002, 3(suppl 2):211-212.
45. Vermaak W, Pinto X, Ponsonnet D, et al.: Heterozygous familial hypercholesterolemia: coadministration of ezetimibe plus atorvastatin [abstract]. Atheroscler Suppl 2002, 3(suppl 2):230-231.
46. Berge KE, Tian H, Graf GA, et al.: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290:1771-1775.
47. Lee MH, Lu K, Hazard S, et al.: Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nature 2001, 27:79-83.
48. Salen G, von Bergmann K, Kwiterovich P, et al.: Ezetimibe is an effective treatment for homozygous sitosterolemia [abstract]. Circulation 2002, 106:11-185.